Biology subjects

Lazar, D. C.

Publications and source records attributed to Lazar, D. C..

4 recordsLinked to original sources

bioRxiv2026

The SLC15A4-LAMTOR1 interaction licenses endolysosomal TLR-mediated mTOR signaling and inflammatory cytokine production

Endolysosomal Toll-like receptors (TLRs) 7-9 are critical mediators of antimicrobial immunity, but their dysregulation drives pathogenic inflammation in autoimmune diseases such as systemic lupus erythematosus (SLE). The endolysosomal solute carrier SLC15A4 is essential for TLR7-9-mediated cytokine production and is strongly linked to SLE susceptibility, yet our understanding of the precise mechanisms by which it coordinates innate immune signaling remains incomplete. Here, we identify a direct interaction between SLC15A4 and LAMTOR1, a core scaffold subunit of the lysosomal Ragulator complex, and show that is required for coupling endolysosomal TLR activation to mTORC1 and downstream inflammatory responses. Structural modeling and site-directed mutagenesis suggest that the 1 helix of LAMTOR1 engages the substrate-binding pocket of SLC15A4, and disruption of this interface broadly suppresses TLR7-9-mediated cytokine production. Notably, this interaction regulates mTOR activation, IRF5/7 signaling, and downstream transcriptional responses through stimulus-dependent mechanisms. These findings define a previously uncharacterized SLC15A4-LAMTOR1 signaling interface that coordinates endolysosomal TLR-mTOR coupling and shapes downstream cytokine output. Significance StatementDysregulated activation of endolysosomal Toll-like receptors (TLRs) 7-9 drives pathogenic inflammatory cytokine responses that underlie autoimmune diseases such as systemic lupus erythematosus. Despite the established role of the endolysosomal transporter SLC15A4 in this process, how it coordinates downstream immune signaling has remained incompletely understood. We show that SLC15A4 directly interacts with LAMTOR1, a core component of the lysosomal Ragulator complex, and that this interaction is required to activate mTOR and engage IRF5/7-dependent inflammatory programs downstream of TLR7-9. Disrupting this interface suppresses type I interferon and cytokine production, identifying the SLC15A4-LAMTOR1 interaction as a central node in endolysosomal innate immune signaling and validating it as a compelling target for therapeutic intervention in interferon-driven autoimmune disease.

immunology↗

bioRxiv2025

Integrated phenotypic screening and chemical proteomics identifies ETF1 ligands that modulate viral translation and replication

Emerging and re-emerging viruses pose a significant threat to global health. Although direct-acting antivirals have shown success, their efficacy is limited by the rapid emergence of drug-resistant viral variants. Hence, there is an urgent need for additional broad spectrum antiviral therapeutic strategies. Here, we identify by phenotypic screening a set of stereochemically defined photoreactive small molecules (photo-stereoprobes) that stereoselectively suppress SARS-CoV-2 replication in human lung epithelial cells. Structure-activity relationship-guided chemical proteomics identified the eukaryotic translation termination factor 1 (ETF1) as a target of the photo-stereoprobes, and this interaction was recapitulated with recombinant purified ETF1. We found that the photo-stereoprobes modulate programmed ribosomal frameshifting mechanisms essential for SARS-CoV-2 infection without causing ETF1 degradation, thus distinguishing the photo-stereoprobes from other known ETF1-directed small molecules. We finally show that the photo-stereoprobes also inhibit the replication of additional viruses with non-canonical ribosomal frameshifting mechanisms. Our findings thus identify a mechanistically distinct class of ETF1 ligands that implicate host translation termination processes as a potential target for antiviral development. SIGNIFICANCE STATEMENTThe identification of broad-spectrum antivirals that target host proteins is a desirable strategy to combat emerging viral infections given the rapid escape potential of viruses and the need to develop new countermeasures for clinically significant pathogens. Here, we integrate phenotypic screening and chemical proteomics to identify photo-stereoprobe small molecules that inhibit the replication of multiple viruses. We show that these compounds bind the protein eukaryotic peptide chain release factor subunit 1 (ETF1) and modulate programmed ribosomal frameshifting. Unlike previously described ligands for ETF1, which lead to proteasomal destruction of the protein, we did not find that the photo-stereoprobes altered ETF1 content in cells. Our findings thus point to an opportunity to pharmacologically modulate a host protein implicated in programmed ribosomal frameshifting as a strategy to combat infection of viruses from different families.

microbiology↗

bioRxiv2022

Chemoproteomics-guided Development of SLC15A4 Inhibitors with Anti-inflammatory Activity

SLC15A4 is an endolysosome-resident transporter that is intimately linked with autoinflammation and autoimmunity. Specifically, SLC15A4 is critical for Toll-like receptor (TLR) 7, 8, and 9 as well as the nucleotide-binding oligomerization domain-containing protein (NOD) 2 signaling in several immune cell subsets. Notably, SLC15A4 is essential for the development of systemic lupus erythematosus in murine models and is associated with autoimmune conditions in humans. Despite its therapeutic potential, to our knowledge no pharmacological tools have been developed that target SLC15A4. Here, we use an integrated chemical proteomics approach to develop a suite of chemical tools, including first-in-class functional inhibitors, for SLC15A4. We demonstrate SLC15A4 inhibitors suppress endosomal TLR and NOD functions in a variety of human and mouse immune cells and provide early evidence of their ability to suppress inflammation in vivo and in clinical settings. Our findings establish SLC15A4 as a druggable target for the treatment of autoimmune/autoinflammatory conditions. One-Sentence SummaryDiscovery and characterization of SLC15A4 inhibitors with anti-inflammatory activity.

immunology↗

bioRxiv2020

ISG15 drives immune pathology and respiratory failure during viral infection

Cytokine storm during respiratory viral infection is an indicator of disease severity and poor prognosis. Type 1 interferon (IFN-I) production and signaling has been reported to be causal in cytokine storm-associated pathology in several respiratory viral infections, however, the mechanisms by which IFN-I promotes disease pathogenesis remain poorly understood. Here, using Usp18-deficient, USP18 enzymatic-inactive and Isg15-deficient mouse models, we report that lack of deISGylation during persistent viral infection leads to severe immune pathology characterized by hematological disruptions, cytokine amplification, lung vascular leakage and death. This pathology requires T cells but not T cell-intrinsic deletion of Usp18. However, lack of Usp18 in myeloid cells mimicked the pathological manifestations observed in Usp18-/- or Usp18C61A mice which were dependent on Isg15. We further mechanistically demonstrate that interrupting the ISGylation/deISGylation circuit increases extracellular levels of ISG15 which is accompanied by inflammatory neutrophil accumulation to the lung. Importantly, neutrophil depletion reversed morbidity and mortality in Usp18C61A mice. In summary, we reveal that the enzymatic function of Usp18 is crucial for regulating extracellular release of ISG15. This is accompanied by altered neutrophil differentiation, cytokine amplification and mortality following persistent viral infection. Moreover, our results suggest that extracellular ISG15 may drive the inflammatory pathology observed and could be both a prospective predictor of disease outcome and a therapeutic target during severe respiratory viral infections.

immunology↗